Biogen

Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder…

The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called…

The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called…

The Swiss drugmaker conducted two identically designed studies, each with about 1,000 participants, who were examined and queried…

Data on the drug has been promising and Biogen and Eisai are expected to file for a US approval soon with a decision expected in…

Biogen said it had submitted responses to the FDA's information requests, which the agency said would require additional time for…

Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective 1st…

The collaboration aims to accelerate the adoption of renewable energy and reduce greenhouse gas emissions within the…

Acting FDA Commissioner Janet Woodcock earlier this month asked the Office of the Inspector General at the Department of Health…

It is the first new treatment approved for Alzheimer's since 2003 and is the first therapy that targets the fundamental…